Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer
LEIDEN, The Netherlands, June 18, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR)announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021.
- LEIDEN, The Netherlands, June 18, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR)announces the appointment of Anurag Relan as Chief Medical Officer (CMO), effective immediately, and Robert Friesen as Chief Scientific Officer, effective from 1 August 2021.
- Anurag and Robert will be the successors of Bruno Giannetti, who was Chief Operating Officer (2006 - 2019) and Chief Medical Officer from 2019.
- Anurag Relan is currently Vice President, Clinical Research and Medical Affairs at Pharming, having held a number of roles within the Company during the past 15 years.
- Prior to his work at Pharming, he was in clinical practice while also teaching medical residents/students.